TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has closed a non-brokered warrant financing. In connection with the closing, the Company issued 3,800,000 warrants at a price of $0.05 per warrant, for gross proceeds of $190,000. Each warrant is exercisable into one common share at an exercise price of $1.00 for a period of 24 months. The warrants are subject to an acceleration right that allows the Company to give notice of an earlier expiry date if the Company’s share price on the CSE (or such other stock exchange the Company’s shares may be trading on) is equal to or greater than $1.30 for a period of 20 consecutive trading days.
The private placement is subject to the approval of the Canadian Securities Exchange (“CSE”) and the securities will be subject to a four-month hold period under securities laws. The Company intends to use the net proceeds from the private placement for working capital purposes.
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.
On behalf of the Board of Directors
Bob Blink, CEO
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73230
News Provided by Newsfile via QuoteMedia
Koios Expands Texas Presence with Upcoming Placements in Select Stores of Drug Emporium, a Pharmacy Chain in TX, AR, LA
Drug Emporium is a chain of “big box” pharmacies in Texas, Arkansas, and Louisiana with standard pharmacy departments as well as “store-within-a-store” features such as “Vitamins Plus”. This month, the Company’s KOIOS™ and Fit Soda™ beverage products will be placed in select Texas locations of Drug Emporium, complementing existing placements of the Company’s products in the state of Texas, including in more than 100 HEB supermarkets.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning this month, all five flavours of its KOIOS ™ nootropic beverage and all four flavours of its Fit Soda ™ functional beverage will be carried in select Texas locations of Drug Emporium, a “big box” pharmacy chain with stores in Texas (population 29 million), Arkansas (population 3 million), and Louisiana (population 4.65 million). In late 2020, the Company announced that its Fit Soda ™ functional beverage product is now carried in more than 100 HEB supermarkets in Texas . Additionally, the Company announced last week that its KOIOS ™ nootropic beverage product was to be added to all locations of Louisiana supermarket chain Matherne’s including its storefront located across from the Louisiana State University’s Tiger Stadium which is the eighth-largest stadium in the world. The Company has sustained its focus on placing its beverage products with regional grocery chains who can play a key role in accelerating market penetration in a given geographic region. By adding to its existing presence in the southeastern United States through local chains such as Drug Emporium and national banner retailers such as Walmart, the Company believes that it is favourably positioned to gain greater market share in the functional beverages category. The Company’s beverage products are currently sold in more than 4,000 stores in the United States.
Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF), is pleased to announce that, further to the Company’s announcement on 15 February 2021, the change of name from World High Life Plc to Love Hemp Group PLC has become effective
All share certificates that are presently in the hands of investors will be valid and do not need to be exchanged for new share certificates.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.